Evidence map›Paper›PMID 25758619›Full record

Trial reportThe journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians2016

Optimising daytime deliveries when inducing labour using prostaglandin vaginal inserts.

Hugh Miller, Laura Goetzl, Deborah A Wing, Barbara Powers, Olof Rugarn

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01127581 (Phase III, Double-blind, Randomized, Multicenter Study of Exogenous Prostaglandin Comparing the Efficacy & Safety of the MVI 200 mcg Versus the Dinoprostone Vaginal Insert), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01127581 phase3completednot on this map

Phase III, Double-blind, Randomized, Multicenter Study of Exogenous Prostaglandin Comparing the Efficacy & Safety of the MVI 200 mcg Versus the Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery in Pregnant Women at Term

TypeinterventionalSponsorFerring PharmaceuticalsRan2010 to 2012Enrolled1,358ConditionsReducing Time to Vaginal Delivery, Cervical Ripening, Induction of LaborArmsMVI 200, Dinoprostone Vaginal Insert (DVI)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Observational
  2. Observational
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Hugh Millera Watching Over Mothers & Babies Foundation , Tucson , AZ , USA .
Laura Goetzlb Department of Obstetrics, Gynecology and Reproductive Sciences , Temple University , Philadelphia , PA , USA .
Deborah A Wingc Department of Obstetrics and Gynecology , University of California , Irvine, Orange , CA , USA .
Barbara Powerse Independent Consultant , Phoenixville , PA , USA , and.
Olof Rugarnf Ferring Pharmaceuticals , Copenhagen , Denmark.
Ferring Pharmaceuticals (Denmark) · DKPhoenixville Hospital · USTemple University · USUniversity of California, Irvine · USWatching Over Mothers & Babies · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine induction start time(s) that would maximise daytime deliveries when using prostaglandin vaginal inserts.

methodsWomen enrolled into the Phase III trial, EXPEDITE (clinical trial registration: NCT01127581), had labour induced with either a misoprostol or dinoprostone vaginal insert (MVI or DVI). A secondary analysis was conducted to determine the optimal start times for induction by identifying the 12-h period with the highest proportion of deliveries by parity and treatment.

resultsOptimal start times for achieving daytime deliveries when using MVI appear to be 19:00 in nulliparae and 23:00 in multiparae. Applying these start times, the median time of onset of active labour would be approximately 08:30 for both parities and the median time of delivery would be the following day at approximately 16:30 for nulliparae and 12:00 (midday) for multiparae. Optimal start times when using DVI appear to be 07:00 for nulliparae and 23:00 for multiparae. Using these start times, the median time of onset of active labour would be the following day at approximately 04:00 and 11:50, and the median time of delivery would be approximately 13:40 and 16:10, respectively.

conclusionsWhen optimising daytime deliveries, different times to initiate induction of labour may be appropriate depending on parity and the type of retrievable prostaglandin vaginal insert used.

Indexed as

Delivery, ObstetricDinoprostoneDouble-Blind MethodDrug Administration ScheduleFemaleHumansLabor, InducedMisoprostolOxytocicsParityPregnancySuppositoriesTime FactorsDinoprostoneMisoprostolOxytocicsSuppositoriesDaytime deliveriesdinoprostoneinduction of labourmisoprostolretrievable prostaglandin vaginal delivery systems

Identifiers

PMID25758619
PMCPMC4776722
OpenAlexW2063748817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.